Two OTC manufacturers warned for inadequate investigations, lax testing and validation practices
Regulatory NewsJoanne S. Eglovitch
Audit/FDA InspectionComplianceNorth AmericaOTCPharmaceuticalsRegulatory NewsJoanne S. EglovitchAudit/FDA InspectionComplianceNorth AmericaOTCPharmaceuticals